Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, First-time-in-human, Dose Ascending Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MP0420 (a Novel Drug Candidate With Potential for Treatment of COVID-19) in Healthy Volunteers

Next Previous
Trial Profile

A Phase 1, First-time-in-human, Dose Ascending Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MP0420 (a Novel Drug Candidate With Potential for Treatment of COVID-19) in Healthy Volunteers

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 19 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ensovibep (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; First in man
  • Sponsors Molecular Partners AG

Most Recent Events

  • 14 Apr 2023 Results reporting safety, tolerability, pharmacokinetic and pharmacodynamic data from this trial published in the British Journal of Clinical Pharmacology
  • 03 Mar 2022 Status changed from recruiting to discontinued due to hypersensitivity observed in 3 subjects, although no stopping rules were met, theSponsor decided to halt recruitment for further investigation. After analysis of PK, i.m.administration was not required, and recruitment stopped.
  • 23 Sep 2021 Planned number of patients changed from 32 to 72.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top